Champions Oncology Inc (CSBR)vsModerna Inc (MRNA)
CSBR
Champions Oncology Inc
$4.92
+1.86%
HEALTHCARE · Cap: $66.95M
MRNA
Moderna Inc
$214.17
+2.98%
HEALTHCARE · Cap: $87.04B
Smart Verdict
WallStSmart Research — data-driven comparison
Moderna Inc generates 3573% more annual revenue ($2.23B vs $60.66M). CSBR leads profitability with a -1.9% profit margin vs -141.4%. CSBR earns a higher WallStSmart Score of 23/100 (F).
CSBR
Avoid23
out of 100
Grade: F
MRNA
Avoid21
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+43.2%
Fair Value
$10.38
Current Price
$4.92
$5.46 discount
Margin of Safety
+69.9%
Fair Value
$134.71
Current Price
$214.16
$79.45 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
Large-cap with strong market position
Conservative balance sheet, low leverage
Areas to Watch
Trading at 17.6x book value
Smaller company, higher risk/reward
ROE of -53.3% — below average capital efficiency
Earnings declined 61.1%
Trading at 12.6x book value
2.1% revenue growth
Weak financial health signals
ROE of -46.6% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : CSBR
CSBR has a balanced fundamental profile.
Bull Case : MRNA
The strongest argument for MRNA centers on Market Cap, Debt/Equity.
Bear Case : CSBR
The primary concerns for CSBR are Price/Book, Market Cap, Return on Equity. Debt-to-equity of 2.82 is elevated, increasing financial risk.
Bear Case : MRNA
The primary concerns for MRNA are Price/Book, Revenue Growth, Piotroski F-Score.
Key Dynamics to Monitor
MRNA carries more volatility with a beta of 1.09 — expect wider price swings.
CSBR is growing revenue faster at 8.8% — sustainability is the question.
CSBR generates stronger free cash flow (-547,000), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
CSBR scores higher overall (23/100 vs 21/100). MRNA offers better value entry with a 69.9% margin of safety. Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Champions Oncology Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Champions Oncology, Inc. develops and sells technology products and solutions to customize the development and use of cancer drugs in the United States. The company is headquartered in Hackensack, New Jersey.
Visit Website →Moderna Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Moderna, Inc., a biotechnology company, develops messenger RNA-based vaccines and therapies for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune diseases. The company is headquartered in Cambridge, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?